Understanding Intracellular Biology to Improve mRNA Delivery by Lipid Nanoparticles

Author:

Hunter Morag Rose1ORCID,Cui Lili1ORCID,Porebski Benjamin Thomas2ORCID,Pereira Sara1,Sonzini Silvia1ORCID,Odunze Uchechukwu1,Iyer Preeti3,Engkvist Ola3ORCID,Lloyd Rebecca Louise4,Peel Samantha4ORCID,Sabirsh Alan5ORCID,Ross‐Thriepland Douglas4,Jones Arwyn Tomos6ORCID,Desai Arpan Shailesh1

Affiliation:

1. Advanced Drug Delivery Pharmaceutical Sciences R&D, AstraZeneca Cambridge CB21 6GH UK

2. Protein and Nucleic Acid Chemistry MRC Laboratory of Molecular Biology Cambridge CB2 0QH UK

3. Molecular AI Discovery Sciences R&D, Astrazeneca Gothenburg 431 50 Sweden

4. Functional Genomics Discovery Sciences R&D, AstraZeneca Cambridge CB4 0WG UK

5. Advanced Drug Delivery Pharmaceutical Sciences R&D, AstraZeneca Gothenburg 431 50 Sweden

6. Cardiff School of Pharmacy and Pharmaceutical Sciences Cardiff University Cardiff CF10 3NB UK

Abstract

AbstractPoor understanding of intracellular delivery and targeting hinders development of nucleic acid‐based therapeutics transported by nanoparticles. Utilizing a siRNA‐targeting and small molecule profiling approach with advanced imaging and machine learning biological insights is generated into the mechanism of lipid nanoparticle (MC3‐LNP) delivery of mRNA. This workflow is termed Advanced Cellular and Endocytic profiling for Intracellular Delivery (ACE‐ID). A cell‐based imaging assay and perturbation of 178 targets relevant to intracellular trafficking is used to identify corresponding effects on functional mRNA delivery. Targets improving delivery are analyzed by extracting data‐rich phenotypic fingerprints from images using advanced image analysis algorithms. Machine learning is used to determine key features correlating with enhanced delivery, identifying fluid‐phase endocytosis as a productive cellular entry route. With this new knowledge, MC3‐LNP is re‐engineered to target macropinocytosis, and this significantly improves mRNA delivery in vitro and in vivo. The ACE‐ID approach can be broadly applicable for optimizing nanomedicine‐based intracellular delivery systems and has the potential to accelerate the development of delivery systems for nucleic acid‐based therapeutics.

Funder

AstraZeneca

Publisher

Wiley

Subject

General Materials Science,General Chemistry

Reference48 articles.

1. Non-viral vectors for gene-based therapy

2. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs

3. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials

4. Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses

5. Moderna Moderna Ships mRNA Vaccine Against Novel Coronavirus (mRNA‐1273) for Phase 1 Study https://investors.modernatx.com/news‐releases/news‐release‐details/moderna‐ships‐mrna‐vaccine‐against‐novel‐coronavirus‐mrna‐1273(accessed: February2020).

Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3